Lupus erythematosus - エリテマトーデス
References
Cutaneous lupus erythematosus (CLE) を特定して分類することは、皮膚に関与する systemic lupus erythematosus と区別するという診断上の課題を引き起こします。最近の研究により、CLE の根底にある遺伝的、環境的、免疫学的要因が明らかになりました。特に薬物誘発は、CLE の最も重要な引き金の 1 つとして浮上しています。治療には、臨床試験で有効性が証明されている belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 などの有望な生物学的製剤を含む局所療法と全身療法が含まれます。
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) ではさまざまな皮膚の問題を取り上げていますが、その一部はより広範な健康上の問題に関連している可能性があります。 acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) などの種類に分類されています。 CCLE は discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus で構成されます。
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus は、体のさまざまな部分に影響を与える可能性のある自己免疫疾患のグループです。 systemic lupus erythematosus (SLE) など複数の臓器に影響を与えるタイプもあれば、 cutaneous lupus erythematosus (CLE) のように主に皮膚に影響を与えるタイプもあります。私たちは臨床徴候、組織検査、血液検査の組み合わせに基づいてさまざまなタイプの CLE を分類していますが、個人差は大きくあります。皮膚の問題は、日光への曝露、喫煙、特定の薬物などの要因によって発生することがよくあります。
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
エリテマトーデス (lupus erythematosus) の原因は明らかではありません。一卵性双生児のうち、一方が罹患した場合、もう一方も罹患する確率は 24% です。女性ホルモン、日光、喫煙、ビタミンD欠乏症、特定の感染症もリスクを高めると考えられています。
治療には、NSAID、コルチコステロイド、免疫抑制剤、ヒドロキシクロロキン、メトトレキサートが含まれる場合があります。コルチコステロイドは効果的ですが、長期間使用すると副作用が生じます。